Expertise in
2
conditions

Jieer F. Ying

Key Laboratory Of Prevention, 
Hangzhou, CN 
Expertise in
2
conditions
Key Laboratory Of Prevention, 
Hangzhou, CN 

Overview

Jieer Ying practices practicing medicine in Hangzhou, China.

Ying is highly rated in 2 conditions, according to our data. Their clinical expertise encompasses Gastroesophageal Junction Cancer, Stomach Cancer, Cholangiocarcinoma (Bile Duct Cancer), Hepato-Pancreato-Biliary Surgery, and Vitrectomy.

They are actively involved in clinical research, co-authoring 81 peer reviewed articles and participating in 4 clinical trials.

Locations

Key Laboratory Of Prevention, Hangzhou, China
Other Locations
Beijing, China
Wenzhou, China
Key Laboratory Of Prevention, China
Jinan, China
Lishui, 323000, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Enrollment Status: Active_not_recruiting
Publish Date: September 01, 2026
Intervention Type: Drug
Study Drugs: Zanidatamab, Tislelizumab, Trastuzumab, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Study Phase: Phase 3
A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drug: ZW25 (Zanidatamab)
Study Phase: Phase 2
A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib as Monotherapy and in Combination With Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib as Monotherapy and in Combination With Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: Sitravatinib, Tislelizumab
Study Phase: Phase 1/Phase 2
A Multicenter, Open-label, Single-arm, Phase Ib Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Gastric Carcinoma
A Multicenter, Open-label, Single-arm, Phase Ib Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Gastric Carcinoma
Enrollment Status: Terminated
Publish Date: March 07, 2024
Intervention Type: Drug
Study Drug: Liposomal Mitoxantrone
Study Phase: Phase 1
View 3 Less Clinical Trials

81 Total Publications

Exploratory genomic stratification of benefit from first-line immunotherapy-based combination in advanced biliary tract cancer: a biomarker analysis of a randomized phase 2 trial.
Exploratory genomic stratification of benefit from first-line immunotherapy-based combination in advanced biliary tract cancer: a biomarker analysis of a randomized phase 2 trial.
Journal: Frontiers in immunology
Published: May 12, 2026

Frequently Asked Questions about Jieer F. Ying

Is Jieer F. Ying a top-rated expert for Gastroesophageal Junction Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Jieer F. Ying is classified as an Advanced expert for Gastroesophageal Junction Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jieer F. Ying participate in research or clinical trials?

Yes. Jieer F. Ying has published 81 articles and abstracts on conditions like Gastroesophageal Junction Cancer. You can view a list of Jieer F. Ying's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ying's expertise for a condition
ConditionClose
      View All 16 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile